drugset
drugset / Trial / NCT00002153

Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders

NCT00002153 ↗

Phase 1 Completed 25 enrolled DEKK-TEC, Inc.
Treatment

Summary

To evaluate topical A-007 in patients with advanced malignancies including Kaposi's sarcoma and lymphoproliferative disorders.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject SIVIFENE Small molecule — Topical

Indications

HIV infectious disease Kaposi's sarcoma lymphoproliferative syndrome